Overview
- 5 inspections across 5 sites are on record.
- 48 Form 483 observations are attributed to this investigator.
- Most recent recorded activity is 2019-09-17.
At a glance
Inspections
5
Sites
5
Observations
48
Career since
Feb 2017
Recent inspections
Most recent inspections in the published record.
| Site | Date | Category | Form 483 |
|---|---|---|---|
| Glaxo Operations UK Ltd | 17 Sep 2019 | Human Drugs | View 483 → |
| Excella GmbH & Co. KG | 10 Aug 2018 | Human Drugs | On file |
| Qilu Pharmaceutical Co., Ltd.(High Tech Zone Site) | 17 Apr 2018 | Human Drugs | On file |
| Simtra Deutschland GmbH | 27 Jun 2017 | Human Drugs | On file |
| Msn Laboratories Private Limited | 3 Feb 2017 | Human Drugs | View 483 → |
Sites inspected
Glaxo Operations UK LtdBarnard Castle, United Kingdom1 insp.
Excella GmbH & Co. KGFeucht, Germany1 insp.
Qilu Pharmaceutical Co., Ltd.(High Tech Zone Site)Jinan, China1 insp.
Simtra Deutschland GmbHHalle (Westf.), Germany1 insp.
Msn Laboratories Private LimitedRangareddy District, India1 insp.
Co-investigators
Investigators who share inspections with this person.
Maya M Davis1 shared
Yvins Dezan1 shared
Laurimer Kuilan-Torres1 shared
Christina A Capacci-Daniel1 shared
Dennis Cantellops Paite1 shared
Linda F Murphy1 shared
Anastasia M Shields1 shared
Full investigator report
Get the verbatim findings behind Kumar G Janoria's 48 observations
Source 483 PDFs, verbatim observations, and how each site responded, so your team knows what they cite before they arrive.
- New inspections and Form 483s, mapped to the CFR citation
- Warning letter outcomes, and the citation patterns they repeat
- Their co-investigators, so no surprises about who shows up on site